Neomidantan (Amantadine Hydrochloride)

Amantadine Hydrochloride, the active ingredient in Neomidantan, is an adamantane antiviral presented as an oral dosage form for oral use. It is employed to treat influenza A infection, manage symptoms of Parkinson's disease, and alleviate drug‑induced extrapyramidal reactions in adult patients.

GNH USA supplies Neomidantan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution rooted in the European Union market. The company ensures quality compliance with EU regulatory standards.

Neomidantan (amantadine hydrochloride) is used in antiviral and neurologic pathways to address specific viral and movement‑disorder conditions.

- Influenza A infection: reduces viral replication and shortens illness duration - Parkinson's disease: improves motor function by enhancing dopamine release - Drug‑induced extrapyramidal symptoms: mitigates rigidity and tremor associated with antipsychotic therapy

Amantadine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Nausea - Insomnia - Headache - Constipation

Serious or Rare Side Effects: - Livedo reticularis (skin discoloration) - Severe skin reactions such as Stevens‑Johnson syndrome - Hallucinations or psychosis - Cardiac arrhythmias - Anaphylactic reactions

Neomidantan requires careful monitoring in several clinical situations.

- Renal impairment: adjust dose and monitor renal function - CNS disorders: observe for confusion or agitation - Cardiovascular disease: use cautiously in patients with arrhythmias - Pregnancy and lactation: risk unknown; prescribe only if benefits outweigh risks - Concomitant CNS depressants: may potentiate sedation - Store at below 25°C: keep in original packaging, protect from moisture

Amantadine can interact with a variety of medicines; some combinations should be avoided while others need close monitoring.

Major Interactions (Avoid): - Anticholinergic agents: may increase central nervous system side effects - QT‑prolonging drugs: heightened risk of cardiac arrhythmia - MAO inhibitors: potential for hypertensive crisis - Other antiviral agents: possible antagonistic effect - Dopamine antagonists: may reduce therapeutic benefit

Moderate Interactions (Monitor Closely): - Renal excretion inhibitors (e.g., NSAIDs): may increase plasma levels - CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation - Live attenuated vaccines: reduced vaccine efficacy - Other dopaminergic drugs: additive dopaminergic activity - Antihypertensives: possible alterations in blood pressure control